ReviewFrontiers in oncology2025
Magnitude and its associated factors of gestational trophoblastic disease in East African countries, systematic review and meta-analysis.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Magnitude and histopathological patterns of gestational trophoblastic disease in Africa: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Prevalence, Associated Factors, and Evaluation of Clinical and Biochemical Indices of Gestational Trophoblastic Tumors in Patients Referring to Imam Reza Hospital, Kermanshah: A Five-Year Analytical Study (2017-2022).Health science reports · 2026Article
- Repurposing statins for choriocarcinoma: targeting the mevalonate pathway to disrupt mechanosignaling and overcome therapeutic resistance.Clinical & experimental metastasis · 2026Review
- Treatment Outcome and Associated Factors Among Women With Gestational Trophoblastic Neoplasia in Northwest Ethiopia: A Multi-Center Retrospective Cohort Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The term of gestational trophoblastic disease (GTD) is used to describe a group of tumors that are characterized by abnormal trophoblastic proliferation. Histologically, GTD includes the pre-malignant partial hydatidiform mole, complete hydatidiform mole, and malignant invasive moles that are choriocarcinoma, placental site trophoblastic tumors, and epithelioid trophoblastic tumors. Method and material: The protocol for this review was registered on PROSPERO, accessible at CRD42024560408. We used the "PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews and Meta-analysis. All original and published cross-sectional, cohort, and case-control types of studies were reported during the study period. Studies conducted in both community and institutional settings were considered. Two reviewers independently assessed the risk of bias in the included studies using tools developed by the Joanna Briggs Institute, which comprise eight criteria. Result: Data was systematically searched by Google Scholar ( Conclusion: This finding revealed that the pooled prevalence of GTD among pregnant women was high. Women who are aged between 30 and 39 years, have a previous history of GTD, and women who have had previous complications during pregnancy, and women who have more than two histories of pregnancy were significantly associated with the outcome variable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.